| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000033962 |
| Receipt No. | R000034910 |
| Official scientific title of the study | Clinical trial of testosterone replacement therapy for the male hypogonadotropic hypogonadism with pituitary or hypothalamic tumor. |
| Date of disclosure of the study information | 2018/08/30 |
| Last modified on | 2019/03/05 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Clinical trial of testosterone replacement therapy for the male hypogonadotropic hypogonadism with pituitary or hypothalamic tumor.
|
|
| Title of the study (Brief title) | T trial | |
| Region |
|
|
| Condition | ||
| Condition | the male hypogonadotropic hypogonadism with pituitary or hypothalamic tumor | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Invetigation for effects of testosterone replacement therapy on quality of life and metabolism in the male hypogonadotropic hypogonadism with pituitary or hypothalamic tumor. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | QOL(short form 36(SF-36), Agingmales' symptoms (AMS)) |
| Key secondary outcomes | metabolic parameter, other hormones |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | teststeron replacement therapy (testosterone enanthate 250mg/4weeks, 48weeks) | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | The patient who satisfies that total teststeron is low and LH is not high, and that other hormone is stable, and who don't receive testosterone or gonadotropin replacement therapy. | |||
| Key exclusion criteria | heart failure(NYHA >3degree), liver disease(AST >100IU/ml or ALT >100IU/ml), kidney disease(Cr >2.0mg/dl), prostatic cancer or PSA >4ng/dl, urinary symptom(IPSS >19points), high-risk for coronary disease (anamnesis of myocardial infarction, stroke, the past of unstable angina in recent three months), insufficient blood pressure control(sBP >160mmHg or dBP >100mmHg), polycytemia(Ht >50%), cognitive functional disorder, assignment hope. In addition, the patient who judged that the medical attendant is inappropriate is excluded. | |||
| Target sample size | 30 | |||
| Research contact person | |
| Name of lead principal investigator | Otsuki Michio |
| Organization | Osaka University Graduate School of Medicine |
| Division name | Department of Metabolic Medicine |
| Address | 2-2, Yamadaoka, Suita-shi, Osaka |
| TEL | 06-6879-3732 |
| otsuki@endmet.med.osaka-u.ac.jp | |
| Public contact | |
| Name of contact person | Mukai Kosuke |
| Organization | Osaka University Graduate School of Medicine |
| Division name | Department of Metabolic Medicine |
| Address | 2-2, Yamadaoka, Suita-shi, Osaka |
| TEL | 06-6879-3732 |
| Homepage URL | |
| mukai@endmet.med.osaka-u.ac.jp | |
| Sponsor | |
| Institute | Department of Metabolic Medicine. Osaka University Graduate School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Nothing |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034910 |